Jan 29 (Reuters) - The U.S. Food and Drug Administration has approved the sale of Evotaz, a once-daily combination pill to treat HIV made by Bristol-Myers Squibb Co, the company said on Thursday.

The new drug combines Reyataz, also known as atazanavir, a Bristol-Myers' protease inhibitor, with cobicistat, a boosting agent produced by Gilead Sciences Inc.

The FDA approval is for use of Evotaz in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

(Reporting By Deena Beasley. Editing by Andre Grenon)